T. Macgregor

发表

D. Lowenthal, K. Matzek, T. Macgregor, 1988, Clinical pharmacokinetics.

Nevirapine and Efavirenz Pharmacokinetics and Covariate Analysis in the 2Nn Study

F. van Leth, J. Beijnen, T. Macgregor, 2005, Antiviral therapy.

Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine

Jing Yuan, Hans Guenter Schaefer, Thorsten Lehr, 2011, Pharmacogenetics and genomics.

Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers

T. Macgregor, A. Hawi, M. Lamson, 1999, Biopharmaceutics & drug disposition.

Nevirapine Induces Both CYP3A4 and CYP2B6 Metabolic Pathways

T. Macgregor, J. Keirns, M. Lamson, 1999 .

Pharmacokinetic Evaluation and Short-Term Activity of Stavudine, Nevirapine, and Nelfinavir Therapy in HIV-1–Infected Adults

T. Macgregor, M. Jacobs, D. Hall, 2004, Journal of acquired immune deficiency syndromes.

A Phenotype–Genotype Approach to Predicting CYP450 and P‐Glycoprotein Drug Interactions With the Mixed Inhibitor/Inducer Tipranavir/Ritonavir

M. Wagner, T. Macgregor, M. Vourvahis, 2010, Clinical pharmacology and therapeutics.

Case-Control Exploration of Relationships Between Early Rash or Liver Toxicity and Plasma Concentrations of Nevirapine and Primary Metabolites

T. Macgregor, D. Hall, 2007, HIV clinical trials.

Are Adverse Events of Nevirapine and Efavirenz Related to Plasma Concentrations?

F. van Leth, J. Beijnen, T. Macgregor, 2005, Antiviral therapy.

The mouse tail-flick method for evaluation of narcotic antagonist sustained release

T. Macgregor, R. H. Reuning, 1987 .

Pharmacokinetic Characterization of Three Doses of Tipranavir Boosted with Ritonavir on Highly Active Antiretroviral Therapy in Treatment-Experienced HIV-1 Patients

F. Goebel, T. Macgregor, J. Sabo, 2010, HIV clinical trials.

Pharmacokinetics, Safety, and Efficacy of Tipranavir Boosted With Ritonavir Alone or in Combination With Other Boosted Protease Inhibitors as Part of Optimized Combination Antiretroviral Therapy in Highly Treatment-Experienced Patients (BI Study 1182.51)

C. Katlama, M. Johnson, A. Lazzarin, 2008, Journal of acquired immune deficiency syndromes.

Pharmacokinetic Characterization of Different Dose Combinations of Coadministered Tipranavir and Ritonavir in Healthy Volunteers

T. Macgregor, S. Norris, L. Galitz, 2004, HIV clinical trials.

In vitro protein binding behavior of dipyridamole.

T. Macgregor, E. Sardi, 1991, Journal of pharmaceutical sciences.

Pharmacokinetics of Nevirapine: Once-Daily Versus Twice-Daily Dosing in the 2NN Study

F. van Leth, J. Beijnen, T. Macgregor, 2005, HIV clinical trials.

Efficacy of oral mexiletine therapy at a 12-h dosage interval.

T. Macgregor, S. Steen, E. M. Hughes, 1990, Chest.

Naltrexone metabolism and sustained release following administration of an insoluble complex to rhesus monkeys and guinea‐pigs

T. Macgregor, R. H. Reuning, J. N. Wiley, 1983, The Journal of pharmacy and pharmacology.

Relative bioavailability of metaproterenol in humans utilizing a single dose, stable isotope approach.

T. Macgregor, K. McKellop, G. Hansen, 1986, Journal of pharmaceutical sciences.

Disposition and biotransformation of the antiretroviral drug nevirapine in humans.

T. Macgregor, J. Keirns, M. Lamson, 1999, Drug metabolism and disposition: the biological fate of chemicals.

Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective study.

T. Macgregor, M. Taub, P. Robinson, 2011, Basic & clinical pharmacology & toxicology.

Pharmacokinetics of BILR 355 after Multiple Oral Doses Coadministered with a Low Dose of Ritonavir

T. Macgregor, C. Ballow, L. Rowland, 2008, Antimicrobial Agents and Chemotherapy.

Pharmacokinetic and Safety Evaluation of BILR 355, a Second-Generation Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers

T. Macgregor, A. Ring, P. Robinson, 2008, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection

T. Macgregor, G. Leitz, C. Yong, 2000, AAPS PharmSci.

Assessment of Nevirapine Bioavailability From Targeted Sites in the Human Gastrointestinal Tract

T. Macgregor, I. Wilding, C. Yong, 2009, Journal of clinical pharmacology.

Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes.

T. Macgregor, H. Woerle, M. Gastonguay, 2014, British journal of clinical pharmacology.

The influence of bacterial gut hydrolysis on the fate of orally administered isonicotinuric acid in man

T. Macgregor, H. Boxenbaum, S. Riegelman, 1974, Journal of Pharmacokinetics and Biopharmaceutics.

Pharmacokinetics of transdermally delivered clonidine

K. Matzek, T. Macgregor, J. Keirns, 1985, Clinical pharmacology and therapeutics.

Steady-State Disposition of the Nonpeptidic Protease Inhibitor Tipranavir when Coadministered with Ritonavir

T. Macgregor, H. Valdez, S. Norris, 2007, Antimicrobial Agents and Chemotherapy.

A 14-Day Dose-Response Study of the Efficacy, Safety, and Pharmacokinetics of the Nonpeptidic Protease Inhibitor Tipranavir in Treatment-Naive HIV-1–Infected Patients

T. Macgregor, H. Valdez, M. Borin, 2004, Journal of acquired immune deficiency syndromes.

In vitro–in vivo correlation for nevirapine extended release tablets

Sreeraj Macha, Thomas R MacGregor, T. Macgregor, 2009, Biopharmaceutics & drug disposition.

Interaction of Ritonavir-Boosted Tipranavir with Loperamide Does Not Result in Loperamide-Associated Neurologic Side Effects in Healthy Volunteers

T. Macgregor, T. Heming, D. Hoelscher, 2005, Antimicrobial Agents and Chemotherapy.

Dipyridamole Bioavailability in Subjects With Reduced Gastric Acidity

T. Macgregor, H. Derendorf, C. VanderMaelen, 2005, Journal of clinical pharmacology.

Steady-state Pharmacokinetics of Nevirapine Extended-release Tablets in HIV-1–infected Children and Adolescents: An Open-label, Multiple-dose, Cross-over Study

C. Königs, C. Giaquinto, T. Macgregor, 2014, The Pediatric infectious disease journal.

Coadministration With Lopinavir and Ritonavir Decreases Exposure to BILR 355, a Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers

T. Macgregor, P. Robinson, M. Castles, 2011, Journal of clinical pharmacology.

Effect of Tipranavir/Ritonavir Combination on the Pharmacokinetics of Tadalafil in Healthy Volunteers

T. Macgregor, P. Dellamonica, N. Rouyrre, 2011, Journal of clinical pharmacology.

Oral pharmacokinetics of pirenzepine in patients with chronic renal insufficiency, failure, and maintenance haemodialysis

K. Matzek, T. Macgregor, J. Keirns, 2004, European Journal of Clinical Pharmacology.

Oral pharmacokinetics of pirenzepine in man following single and multiple doses

K. Matzek, T. Macgregor, J. Keirns, 1986 .

Quantitation of five nevirapine oxidative metabolites in human plasma using liquid chromatography-tandem mass spectrometry.

T. Macgregor, L. Rowland, Rand G. Jenkins, 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Effect of food and antacids on the oral absorption of pirenzepine in man

K. Matzek, T. Macgregor, J. Keirns, 1986 .

Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes

Marc R Gastonguay, Alexander Staab, Sreeraj Macha, 2013, Journal of clinical pharmacology.

Analysis of chlorthalidone in biological fluids by high-performance liquid chromatography using a rapid column cleanup procedure.

T. Macgregor, J. Keirns, M. Hagopian, 1984, Therapeutic drug monitoring.

Pharmacokinetic Assessment of Nevirapine and Metabolites in Human Immunodeficiency Virus Type 1-Infected Patients with Hepatic Fibrosis

T. Macgregor, J. Mallolas, A. M. Cammett, 2009, Antimicrobial Agents and Chemotherapy.